Core Viewpoint - Marker Therapeutics, Inc. has received a 9.5 million grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to support the clinical investigation of its lead asset MT-601 in patients with metastatic pancreatic cancer [1][5]. Funding and Grants - The CPRIT grant will support the Phase 1 PANACEA study evaluating the safety and tolerability of MT-601 in patients with metastatic pancreatic cancer [2]. - Including the CPRIT grant, the company has secured over 30 million in non-dilutive funding from various governmental institutions, including a recent $2 million grant from the NIH Small Business Innovation Research (SBIR) program [5][6]. Clinical Trials and Research - MT-601 is currently being studied in patients with CD19-CAR relapsed lymphoma, with preliminary safety and efficacy data showing sustained objective responses in three participants [3]. - Previous studies at Baylor College of Medicine indicated that multiTAA-specific T cells, similar to MT-601, demonstrated a favorable safety profile and durable cancer control in pancreatic cancer patients [4]. Product Overview - MT-601 is a multi-tumor associated antigen (multiTAA)-specific T cell product that targets six different tumor antigens upregulated in cancer cells [7]. - The product utilizes a non-genetically modified approach, which may offer easier and less expensive manufacturing with an improved safety profile compared to current engineered T cell therapies [8]. Company Background - Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on developing next-generation T cell-based immunotherapies for hematological malignancies and solid tumors [9]. - The company aims to introduce novel T cell therapies to the market while prioritizing financial resource preservation and operational excellence [9].
Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer